BRAK and APRIL as novel biomarkers for ovarian tumors.

导出原文传递

翻译打印收藏纠错

作者： Heeyon,Kim ^[1] ; Bo Hee,Won ^[2] ; Jae Il,Choi ^[1] ; Inha,Lee ^[3] ; Jae Hoon,Lee ^[2] ; Joo Hyun,Park ^[4] ; Young Sik,Choi ^[1] ; Jae-Hoon,Kim ^[2] ; SiHyun,Cho ^[2] ; Jong-Baeck,Lim ^[5] ; Byung Seok,Lee ^[2]

作者单位： Department of Obstetrics & Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 06273, South Korea. ^[1] Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, 03722, South Korea. ^[2] Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, 03722, South Korea. ^[3] Department of Obstetrics & Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, South Korea. ^[4] Department of Obstetrics & Gynecology, Yongin Severance Hospital, Yonsei University College of Medicine, Gyeonggi-do, 16995, South Korea. ^[5] Hanaro Medical Foundation, Seoul, 03159, South Korea. ^[6]

关键词 APRIL/TNFSF13 BRAK/CXCL14 CA-125 biomarker ovarian tumor

主题词 CA-125抗原(CA-125 Antigen);趋化因子, CXC(Chemokines, CXC);女(雌)性(Female);人类(Humans);卵巢肿瘤(Ovarian Neoplasms);ROC曲线(ROC Curve);肿瘤坏死因子配体超家族成员13(Tumor Necrosis Factor Ligand Superfamily Member 13)

DOI 10.2217/bmm-2021-1014

PMID 35588310

发布时间 2022-08-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交